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Summary Tumour was obtained from 37 patients with oestrogen receptor-positive breast cancer, before and
during treatment with tamoxifen, and examined qualitatively and semi-quantitatively for mRNA of the three
mammalian TGF-/ isoforms. Levels of TGF-3 isoforms were then correlated with tumour response to
tamoxifen, as assessed by monthly ultrasound. A high incidence of expression of each isoform was found in
tumour material taken both before and during treatment. Semiquantitative assessment of mRNA showed that
in the majority of tumours, expression of TGF-#s did not change markedly with treatment, i.e. beyond that
which might have been caused by method reproducibility and tumour heterogeneity (variations of< 100%
between pre- and post-treatment samples). In those displaying significant variation with treatment, expression
of TGF-fl, and -A3 increased or decreased in equal numbers, whereas TGF-fl2 expression tended to increase
with treatment. Subdividing tumours by clinical response revealed no significant association between changes in
expression ofTGF-fi, and TGF-fl3. There was, however, a significant correlation between changes in expression
ofTGF-#2 and response (P =0.018). Thus, of 15 responding tumours displaying substantial changes, 11 showed
an increase in TGF-fl2 expression with treatment, whereas none of the non-responding tumours were associated
with increased expression. While not providing evidence for a generalised increase in TGF-/ expression with
tamoxifen treatment, the present study suggests that response to tamoxifen therapy may be associated with an
increase in expression of specific TGF-# isoforms in some, but not all, tumours.
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Tamoxifen is widely used in the treatment of post-
menopausal breast cancer. Because benefits are usually
observed in patients with oestrogen receptor-positive
tumours (Stewart, 1989), it appears that the primary effects
of tamoxifen are modulated by competitive antagonism of
oestrogen at its receptor (Katzenellenbogen et al., 1983;
Berthois et al., 1986). However, anti-tumour effects may be
mediated secondarily through the action of inhibitory growth
factors such as the transforming growth factor betas (TGF-
fls) (Butta et al., 1992). TGF-#s have been reported to be
inhibitory to breast epithelial cells (Lippman et al., 1987;
Travers et al., 1988; Barrett-Lee et al., 1990; Knabbe et al.,
1991; Mizukami et al., 1991), and their expression in breast
tissues can be modified by tamoxifen (Salomon et al., 1989;
Colletta et al., 1990; Sporn et al., 1990; McCune et al., 1992;
Butta et al., 1992; Ji et al., 1994). However, TGF-# can also
act in a stimulatory fashion (Torre-Amione et al., 1990;
Arrick et al., 1992; Arteaga et al., 1993; Chang et al., 1993),
and high levels of TGF-,B mRNA and protein have been
associated with poor prognosis in patients with breast cancer
(Dickson et al., 1987; King et al., 1989; Colletta, 1990; Welch
et al., 1990; Thompson et al., 1991; Gorsch et al., 1992;
Walker and Dearing, 1992; MacCallum et al., 1994; Walker
et al., 1994).
Assessments of the role of TGF-,Bs in the behaviour of
breast cancer are also complicated by factors such as (1)
TGF-f3 may be synthesised in one cell type and have its
action in another (Lafyatis et al., 1990; Jackowlew et al.,
1992); (2) a variety of forms may exist, not all of which are
active (Colletta et al., 1991); (3) mRNA and protein levels do
not always correlate, and may be differentially regulated
(Knabbe et al., 1987; Colletta et al., 1994). There is thus a
need to clarify the role of TGF-,B in the natural history of
breast cancer and in mediating responses to tamoxifen. To do
this we have investigated a group of elderly patients offered
primary systemic therapy with tamoxifen before definitive
breast surgery. The design of the study has allowed us to (1)
observe the effects of tamoxifen treatment on the mRNA
isoforms of TGF-f by comparing measurements in the same
primary breast cancer both before and after treatment; and
(2) to relate changes in expression of TGF-# following
tamoxifen treatment with response as measured by monitor-
ing tumour volume during treatment.
Materials and methods
Patients
Thirty-seven patients over 70 years of age and presenting
with histologically proven primary breast cancer to the
Edinburgh Breast Unit were entered into a study in which
primary systemic therapy with tamoxifen was offered. All
patients had tumours>3 cm in size which were ER-rich
(>20 fmol mg-' protein cytosol, Anderson et al., 1989).
Therapy (tamoxifen, 20 mg day-1) was administered initially
for 3 months, but patients could be electively treated for an
extended period of time up to a maximum of 10 months, at
the end of which definitive breast surgery was performed.
Response to treatment was assessed by monthly ultrasound
of the breast (Forouhi et al., 1994), and patients were
classified as being responders if there was a decrease in
tumour volume of at least 20% between initial biopsy and
final surgery; non-responders showed either no change or an
increase in tumour volume. By these criteria, 27 responded to
tamoxifen and 10 did not. Although the time of treatment
was variable, 32 patients showed progressive changes in
tumour size. However, one responding patient did not
experience a decrease in tumour volume of 20% until 6
months (and therefore, if classified at 3 months, would have
been a non-responder), whereas, conversely, a further four
patients categorised as non-responders experienced some
degree of tumour shrinkage at earlier time points.
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Tumour tissue was taken before treatment and following
primary tamoxifen treatment, snap frozen and stored in
liquid nitrogen until extracted for RNA.
RNA Extraction
Tumour RNA was extracted using a modification of the
method of Auffrey and Rougeon (1980). Tumour tissue
(minimum 0.2 g) was dismembranated and resuspended in
3 M lithium chloride-6 M urea (6 ml) before being sonicated
and left overnight at 4°C to allow nucleic acids to precipitate.
Total mRNA was then recovered by centrifugation (15 000 g)
and digested in 10 mM Tris/sodium dodecyl sulphate (SDS)
(6 ml) containing proteinase K (50 ,ug ml-'). Protein was
removed using 100% phenol (pre-equilibrated with 0.1M Tris,
pH 7.4), followed by phenol-chloroform-isoamyl alcohol
25:24:1, v/v/v) and 100% chloroform by centrifugation, with
the aqueous phase recovered on each occasion. The RNA
was then precipitated overnight in absolute alcohol (2.5
volumes) containing lithium chloride (300 pl, 8 M), and
recovered by centrifugation (4000 g, 4°C for 45 min), dried
and resuspended in diethyl pyrocarbonate-treated water.
RNA content and purity were assessed by spectrophotome-
try at 260 nm and 280 nm, and aliquots stored at -80°C
until assayed.
RNAase protection assay
Probes were prepared as set out in Bartlett et al., (1992),
using a Gemini II system (Promega, UK) with full-length
transcripts isolated by polyacrylamide gel electrophoresis.
Bands eluted from the gel were resuspended in hybridisation
buffer for use in the RNAase protection assay. This assay
was also carried out according to Bartlett et al., (1992).
Sample probe hybrids remaining after digestion with
RNAase were denatured and separated by gel electrophor-
esis. Autoradiographs of the paired RNA samples were
assessed by scanning densitometry for changes in expression
of the three isoforms occurring during treatment with
tamoxifen.
Quantitation
Densitometry results were normalised to actin controls, and
changes in expression of TGF-,B mRNA defined using several
controls. These included (1) replicates of the tumour pairs
run on different occasions, to assess reproducibility of
measurements (greatest variation+68%); (2) different RNA
extracts of the same tumour to determine heterogeneity
within the tumour sample (greatest variation+66%); and (3)
three patients studied sequentially over 3-7 weeks without
intervening therapy to assess variations associated with no
treatment (greatest variation+91%). An arbitrary cut off
value of+ 100% was chosen to define any changes as
significant and attributable to tamoxifen therapy.
Statistical analysis
Analysis of the results generated was carried out using the
chi-squared test for trend.
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The expression of mRNA for the three isoforms ofTGF-,B in
pretreated and treated tumour samples is shown in Table I.
TGF-fl, was expressed in all tumours before treatment, but
following therapy, two cancers lost expression (one respond-
ing and one non-responding tumour). TGF-32 was expressed
initially by 33 of 37 tumours, and during treatment in 35 of
37 (this included 32 of the tumours which initially showed
expression); TGF-#3 expression was detected in 36 of 37
pretreatment and in all post-treatment samples. Therapy had
no significant effects on the incidence of expression of TGF-fB
isoforms within the total group, or between subgroups of
responding and non-responding patients.
Quantitative analysis
Limits for normal variations in the expression ofTGF-# were
determined using several controls (see Materials and
methods); changes in excess of+ 100% were regarded as
substantial and potentially attributable to tamoxifen treat-
ment. The autoradiograph in Figure 1 shows typical examples
of tumours studied before and after treatment with
tamoxifen; paired RNA samples being hybridised to a
TGF-#2 probe. Patient 1 illustrates substantially increased
expression with treatment, patient 2 very little change in
expression, and in patient 3, a substantial decrease in level of
expression with treatment. As is shown in Table II, the
majority of tumours showed no substantial changes with
treatment for TGF-fl, and -/33 expression, and those that did
were as likely to display an increase as a decrease. For TGF-
/2, more tumours showed changes in expression, these being
predominantly increased expression after treatment.
When tumours were subdivided into responding and non-
responding groups, no significant associations were found
between groups for changes in expression ofTGF-1l3 and -/3
mRNA. However, there was a significant association between
increasing expression ofTGF-/32 and response (P= 0.018, chi-
squared test for trend); indeed no non-responding patients
showed an increase in TGF-fl2, whereas 11 of 27 responding
did so.
Discussion
The management of patients with primary systemic therapy








Figure 1 Illustrative autoradiograph. Paired samples of pre- and
post-treatment RNA from three patients hybridised to a TGF-f32
RNA probe (600bp).
Table I Incidence of expression of mRNA for the three isoforms of TGF-,B in pre- and post-treatment samples
Pre-treatment Post-treatment
Total (37) R (27) NR (10) Total (37) R (27) NR (J0)
TGF-fi,l 37 27 10 35 26 9
TGF-f2 33 26 7 36 26 9
TGF-A3 36 26 10 37 27 10
R, responders; NR, non-responders.Changes in TGF-,B expression on treatnent
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Table II Changes in expression of TGF-,B mRNA levels outwith normal variation (± 100%) and response to treatment
TGF-f, TGF-#2 TGF-#3
Total (37) 7 25 5 11 22 4 6 27 4
Responders (27) 6 17 4 11 14 2 5 21 1
Non-responders (10) 1 8 1 0 8 2 1 6 3
X2 test for trend P=0.724 P=0.018 P=0.069
on individual tumours in situ both in terms of clinical
response and biological parameters. In this particular study
effects of tamoxifen therapy on tumour expression of mRNA
for the isoforms of TGF-# have been monitored and
correlated with the response of individual cancers. The
results show that almost all tumours express each isoform
both before and after treatment, and that the majority of
tumours do not show substantial changes in TGF-,B
expression with treatment. However, significant changes in
one isoform, TGF-#2 were more frequently observed with
therapy; with a correlation between response to therapy and
increasing TGF-#2 expression.
The high incidence of TGF-# mRNA expression is in
keeping with our own previously published work (MacCal-
lum et al., 1994), and that of others (Arrick et al., 1990;
Barrett-Lee et al., 1990; Jeng et al., 1993), and is consistent
with the high frequency of protein expression in primary
breast cancers (McCune et al., 1992; Gorsch et al., 1992;
Jhala et al., 1995). Perhaps because of this high expression,
TGF-,B isoform status did not change with treatment.
However, level of expression did appear to vary between
pre- and post-treatment samples, and therefore we attempted
to quantify the level of expression and relate changes to
response to treatment. In order to attribute changes more
reliably to the influence of tamoxifen, efforts were made to
assess the inherent variability of the methodology, the
heterogeneity of the tumours, and the variation associated
with sequential sampling of the same cancer without
intervening therapy. Results from representative samples
suggested that differences of up to 100% could result from
repeated assay of different portions of the same tumour. In
analysing the results therefore, it was decided to consider
variations in excess of 100% as being significant changes.
Using this criterion, in the majority of tumours we were
unable to detect major changes in expression attributable to
treatment, irrespective of whether the tumour displayed a
therapeutic response or not. While, to our knowledge there
has been no other published data correlating mRNA
expression of TGF-,B isoforms with effect of tamoxifen in
primary breast tissue, these observations would be consistent
with work on breast cancer cell lines, in the majority ofwhich
tamoxifen does not apparently affect mRNA levels (Knabbe
et al., 1987; Arrick et al., 1992; Jeng et al., 1993; Colletta et
al., 1994). This contrasts with studies in which TGF-,Bhas
been examined at the level of protein. Most of these
investigations have suggested that tamoxifen induces TGF-
,B, in particular the TGF-/3, isoform. A single study has
examined a small number of individual breast cancers before
and after 3 months of treatment with tamoxifen (Butta et al.,
1992), and reported increased levels ofTGF-3,B in the stromal
compartment of tumours (although that in epithelial cells
remained constant). These differences between mRNA and
protein expression may result from the synthesis of different
isoforms in different cell compartments of tumours (Lafyatis
et al., 1990; Jakowlew et al., 1992), and the sequestration of
mature protein by fibroblasts (McCune et al., 1992; Dublin et
al., 1993).
Although we did not observe a general induction of TGF-
/ mRNA with tamoxifen therapy, it was of interest that
approximately one-third of tumours showed an increase in
TGF-/32 isoform on treatment, and that all these tumours
responded to therapy. While this is compatible with
tamoxifen's inductive influences on TGF-,Bprotein (Colletta
et al., 1991; Butta et al., 1992; Jordan et al., 1993), it should
be noted that the effect on protein is on the /3, isoform,
whereas the mRNA affected in the present study is TGF-/32.
The present study provides evidence of differential regulation
of different isoforms of TGF-,B, in that only one of the 11
tumours displaying an increase in TGF-#2 expression also
shows an increase in levels ofTGF-/3, mRNA. Similarly, only
4 of the 11 tumours showing increased TGF-fl2 also have
increased TGF-#3 (one tumour showing increased expression
of all three isoforms). Interestingly, 17 of 27 tumours in the
responding group displayed increased expression of one of
the three isoforms ofTGF-/3 compared with one of ten in the
non-responding group (increased TGF-,B, and -3).
Given that TGF-,Bs generally inhibit growth of breast
cancer epithelium (Roberts et al., 1985; Moses et al., 1985),
the induced response of TGF-,B following tamoxifen
treatment would be compatible with tumour regression. As
a result it has been suggested that TGF-/ may mediate
tamoxifen anti-tumour properties (Lippman et al., 1987;
Knabbe et al., 1991). If this is the case, it needs to be asked
why in the present study a substantial proportion of
responding tumours do not show increases in TGF-P. There
are several potential reasons for this. Firstly, it may be that
TGF-,Bs were induced by tamoxifen, but at an earlier time
point than that at which mRNA analyses were performed;
indeed if the induction mediates anti- tumour effects it would
be expected to precede tumour response. We cannot exclude
this possibility as all our patients received at least 3 months'
treatment so that evidence of tumour regression could be
obtained, and it was only at this time that tumour samples
were taken for analysis. However, length of treatment with
tamoxifen did not appear to influence results, in that over the
comparatively large range of treatment times, there was no
evidence for greater induction ofTGF-/s at early time points.
A further consideration surrounds compartmentalisation of
TGF-/ between malignant epithelium and stromal elements
of the tumour. In situ hybridisation studies suggest that the
major site of mRNA expression is in the malignant epithelial
cells (MacCallum et al., 1995; Auivenin et al., 1995; Walker
and Gallacher, 1995), and thus regression of this compart-
ment would diminish the major cellular site of synthesis.
However, if TGF-,B protein is sequestered by the stromal
component (McCune et al., 1992; Dublin et al., 1993) which
did not regress on treatment, an impression of up-regulation
may be produced at a time when mRNA levels are reduced.
A further potential reason for the non-elevation of TGF-
/3s in responding tumours is that TGF-#s may not mediate
tamoxifen's anti-tumour effects (Ji et al., 1994), which depend
on other mechanisms, for example, the presence and
concentration of other growth factors or cytokines within
the tumour environment (Pepper et al., 1993). Indeed there is
accumulating evidence that with progression to more
advanced disease resistance to TGF-#s can develop (Schultz
and Grant, 1991; Kerbel et al., 1993) in melanoma (Kerbel et
al., 1992), colon cancer (Manning et al., 1991) and mouse
mammary cancer (Pierce et al., 1995).
The present study illustrates the complexity of investigat-
ing the effects of treatment on biological parameters in
clinical specimens. Further questions are raised which can
only be answered by more in-depth studies, including
investigations involving the measurement of mRNA, protein
and biological activity at time points preceding clinical
response.Changes in TGF-,B expression on treatment
J MacCallum et al
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